Biofrontera Inc

Research Biofrontera Inc (BFRI) on Bullrun: market cap USD 19.33M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 19.33M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 41.71M-USD 10.54M-USD 13.36M73.7%-1.04USD 6.39MUSD 6.16MUSD 10.48M
FY2024USD 37.32M-USD 17.76M-USD 10.28M50.1%-3.22USD 5.91MUSD 4.92MUSD 4.43M
FY2023USD 34.07M-USD 20.13M-USD 24.90Mn/a-13.02USD 1.34MUSD 3.90MUSD 4.79M
FY2022USD 28.67M-USD 640.00K-USD 16.24Mn/a-0.61USD 17.21Mn/aUSD 23.88M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 19.33Mn/an/an/a
20252025-12-31USD 6.64Mn/an/an/a
20242024-12-31USD 9.67Mn/an/an/a
20232023-12-29USD 4.20Mn/an/an/a
20222022-12-30USD 24.48Mn/an/an/a
20212021-12-31USD 128.62Mn/an/an/a

About Biofrontera Inc

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Biofrontera Inc's market cap?

Biofrontera Inc's market capitalization is USD 19.33M.

What does Biofrontera Inc do?

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.